Search

BACKGROUND: Reduced MS disease activity with alemtuzumab versus subcutaneous interferon beta-1a (SC IFNB-1a) in core phase 2/3 studies was accompanied by increased incidence of infections that were mainly nonserious and...

Alemtuzumab Disease-modifying therapy Infection relapsing-remitting multiple sclerosis Safety Adult Alemtuzumab Antibodies Monoclonal Humanized Disease Susceptibility Female Humans Infections Interferon beta-1a Male Multiple Sclerosis Recurrence Risk Factors Time Factors

Original Communication Alemtuzumab Multiple Sclerosis Disease-modifying therapy EFFICACY Safety Long-term

Alemtuzumab Disease-modifying therapy EFFICACY Long-term Multiple Sclerosis Safety Alemtuzumab Antibodies Monoclonal Humanized Follow-Up Studies Humans Interferon beta-1a Multiple Sclerosis Relapsing-Remitting

Alemtuzumab disability Disease-modifying therapy Expanded Disability Status Scale Functional systems Multiple Sclerosis Adult Alemtuzumab Antibodies Monoclonal Humanized Female Humans Male Multiple Sclerosis Relapsing-Remitting Nervous System Diseases Single-Blind Method

BACKGROUND: Autoimmune disorders including nephropathies have been reported more frequently in alemtuzumab-treated multiple sclerosis (MS) patients than in the general population. OBJECTIVE: Describe instances of autoimmune...

Alemtuzumab anti-glomerular basement membrane disease Disease-modifying therapy membranous glomerulonephropathy Multiple Sclerosis Nephropathy Adult Alemtuzumab Female Follow-Up Studies glomerulonephritis glomerulonephritis Membranous Hemorrhage Humans Immunologic Factors Incidence Lung Diseases Male Multiple Sclerosis Relapsing-Remitting